KR20160054570A - 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 - Google Patents

통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 Download PDF

Info

Publication number: KR20160054570A
Authority: KR; South Korea
Prior art keywords: compound; pain; chloro; compounds; compound according
Prior art date: 2013-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020167009294A

Other languages

English (en)

Korean (ko)

Inventor

올가 바비크

티나 게리안테스

로버츠 제트. 루오

데이비드 제이. 폴링

스리니바산 피. 벤카타찰란

야닐린 왕-피셔

Original Assignee

크로모셀 코포레이션

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-10

Filing date

2014-09-09

Publication date

2016-05-16

2014-09-09 Application filed by 크로모셀 코포레이션 filed Critical 크로모셀 코포레이션

2016-05-16 Publication of KR20160054570A publication Critical patent/KR20160054570A/ko

Status Ceased legal-status Critical Current

Links

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Thiazole And Isothizaole Compounds (AREA)

KR1020167009294A 2013-09-10 2014-09-09 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자 Ceased KR20160054570A (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361876046P	2013-09-10	2013-09-10
US61/876,046		2013-09-10
PCT/US2014/054764 WO2015038533A2 (en)	2013-09-10	2014-09-09	Sodium channel modulators for the treatment of pain and diabetes

Publications (1)

Publication Number	Publication Date
KR20160054570A true KR20160054570A (ko)	2016-05-16

Family

ID=52666496

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020167009294A Ceased KR20160054570A (ko)	2013-09-10	2014-09-09	통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자

Country Status (18)

Country	Link
US (2)	US20160221974A1 (2)
EP (1)	EP3043787B1 (2)
JP (1)	JP6445565B2 (2)
KR (1)	KR20160054570A (2)
CN (1)	CN105611923B (2)
AU (1)	AU2014318979B2 (2)
BR (1)	BR112016005271A2 (2)
CA (1)	CA2922851C (2)
ES (1)	ES2687598T3 (2)
IL (1)	IL244506B (2)
MX (1)	MX2016002881A (2)
MY (1)	MY181928A (2)
PH (1)	PH12016500296A1 (2)
RU (1)	RU2016113156A (2)
SG (2)	SG10201805552PA (2)
UA (1)	UA120353C2 (2)
WO (1)	WO2015038533A2 (2)
ZA (1)	ZA201702410B (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2687481T3 (es) *	2013-03-15	2018-10-25	Chromocell Corporation	Moduladores del canal de sodio para el tratamiento del dolor
AU2014318979B2 (en)	2013-09-10	2019-03-28	Chromocell Corporation	Sodium channel modulators for the treatment of pain and diabetes
EP3193610A4 (en) *	2014-09-09	2018-04-04	Chromocell Corporation	Selective nav1.7 inhibitors for the treatment of diabetes
EP3390374B1 (en)	2015-12-18	2020-08-26	Merck Sharp & Dohme Corp.	Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
HRP20250505T1 (hr)	2016-05-20	2025-06-20	Xenon Pharmaceuticals Inc.	Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
CN106084535A (zh) *	2016-06-02	2016-11-09	扬州兰都塑料科技有限公司	一种耐刮擦的电力电缆的制备方法
CN105924670A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种电力电缆用耐磨剂
CN105924843A (zh) *	2016-06-02	2016-09-07	扬州兰都塑料科技有限公司	一种耐刮擦的电力电缆
ES2967410T3 (es)	2016-12-09	2024-04-30	Xenon Pharmaceuticals Inc	Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
CN106892845B (zh) *	2017-02-28	2018-10-30	四川同晟生物医药有限公司	一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) *	2018-04-13	2019-10-17	Chromocell Corporation	Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) *	2018-05-11	2019-11-14	Chromocell Corporation	Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
CN112262142B (zh)	2018-06-13	2023-11-14	泽农医药公司	苯磺酰胺化合物及其作为治疗剂的用途
MX2021001380A (es)	2018-08-31	2021-05-27	Xenon Pharmaceuticals Inc	Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53488A (fr)	2018-08-31	2021-12-08	Xenon Pharmaceuticals Inc	Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
CN113527281B (zh) *	2020-04-20	2023-12-22	昆山彭济凯丰生物科技有限公司	杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5356897A (en)	1991-09-09	1994-10-18	Fujisawa Pharmaceutical Co., Ltd.	3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
DE50207103D1 (en) *	2001-03-14	2006-07-20	Gruenenthal Gmbh	Substituierte pyrazolo- und thiazolopyrimidine als analgetika
US7659082B2 (en)	2002-02-19	2010-02-09	Xenon Pharmaceuticals Inc.	Methods for identifying analgesic agents
AU2003243921B2 (en)	2002-06-27	2009-05-07	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
GB0324792D0 (en)	2003-10-23	2003-11-26	Sterix Ltd	Compound
US7449477B2 (en)	2003-11-25	2008-11-11	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
CA2564355C (en)	2004-05-07	2012-07-03	Amgen Inc.	Protein kinase modulators and method of use
AU2005266090A1 (en) *	2004-07-23	2006-02-02	Pfizer Inc.	Pyridine derivatives
US20090093485A1 (en)	2004-10-29	2009-04-09	Astrazeneca Ab	Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
UA96283C2 (uk) *	2005-12-23	2011-10-25	Зіланд Фарма А/С	Модифіковані міметики лізину
AU2008213836A1 (en) *	2007-02-05	2008-08-14	Xenon Pharmaceuticals Inc.	Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
US8124610B2 (en)	2007-07-13	2012-02-28	Icagen Inc.	Sodium channel inhibitors
WO2009012241A1 (en)	2007-07-13	2009-01-22	Icagen, Inc.	Sodium channel inhibitors
PE20120008A1 (es) *	2009-01-12	2012-01-24	Icagen Inc	Derivados de fenoxi bencenosulfonamida
CN105254557A (zh)	2009-05-29	2016-01-20	拉夸里亚创药株式会社	作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
JP2013525368A (ja)	2010-04-23	2013-06-20	キネタ・インコーポレイテツド	抗ウイルス性化合物
ES2526675T3 (es)	2010-07-09	2015-01-14	Pfizer Limited	N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
CA2804593C (en) *	2010-07-09	2015-11-24	Pfizer Limited	Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
JP5872552B2 (ja)	2010-07-09	2016-03-01	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	化学化合物
JP2013536165A (ja)	2010-07-12	2013-09-19	ファイザー・リミテッド	痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
JP2014507136A (ja)	2011-01-18	2014-03-27	アムジエン・インコーポレーテツド	ＮａＶ１．７ノックアウトマウスとそれらの使用
UY34171A (es) *	2011-07-01	2013-01-31	Gilead Sciences Inc	Compuestos heterocíclicos fusionados como moduladores del canal iónico
MX2014001851A (es)	2011-08-17	2014-10-24	Amgen Inc	Inhibidores del canal de heteroarilo sodio.
WO2013043925A1 (en) *	2011-09-21	2013-03-28	Gilead Sciences, Inc.	Sodium channel blockers reduce glucagon secretion
JP6014155B2 (ja)	2011-10-31	2016-10-25	ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
CA2890897A1 (en)	2012-11-14	2014-05-22	The Board Of Regents Of The University Of Texas System	Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
ES2687481T3 (es) *	2013-03-15	2018-10-25	Chromocell Corporation	Moduladores del canal de sodio para el tratamiento del dolor
PL3417851T3 (pl)	2013-09-09	2020-12-14	Peloton Therapeutics, Inc.	Etery arylowe i ich zastosowanie
AU2014318979B2 (en)	2013-09-10	2019-03-28	Chromocell Corporation	Sodium channel modulators for the treatment of pain and diabetes
EP3193610A4 (en)	2014-09-09	2018-04-04	Chromocell Corporation	Selective nav1.7 inhibitors for the treatment of diabetes

2014
- 2014-09-09 AU AU2014318979A patent/AU2014318979B2/en not_active Ceased
- 2014-09-09 US US15/021,153 patent/US20160221974A1/en not_active Abandoned
- 2014-09-09 EP EP14843353.5A patent/EP3043787B1/en active Active
- 2014-09-09 MY MYPI2016700824A patent/MY181928A/en unknown
- 2014-09-09 SG SG10201805552PA patent/SG10201805552PA/en unknown
- 2014-09-09 WO PCT/US2014/054764 patent/WO2015038533A2/en not_active Ceased
- 2014-09-09 ES ES14843353.5T patent/ES2687598T3/es active Active
- 2014-09-09 RU RU2016113156A patent/RU2016113156A/ru not_active Application Discontinuation
- 2014-09-09 BR BR112016005271-4A patent/BR112016005271A2/pt not_active IP Right Cessation
- 2014-09-09 CN CN201480049690.8A patent/CN105611923B/zh not_active Expired - Fee Related
- 2014-09-09 SG SG11201601367QA patent/SG11201601367QA/en unknown
- 2014-09-09 MX MX2016002881A patent/MX2016002881A/es active IP Right Grant
- 2014-09-09 CA CA2922851A patent/CA2922851C/en active Active
- 2014-09-09 UA UAA201603676A patent/UA120353C2/uk unknown
- 2014-09-09 KR KR1020167009294A patent/KR20160054570A/ko not_active Ceased
- 2014-09-09 JP JP2016540921A patent/JP6445565B2/ja active Active
2016
- 2016-01-13 US US14/994,846 patent/US9458118B2/en active Active
- 2016-02-12 PH PH12016500296A patent/PH12016500296A1/en unknown
- 2016-03-09 IL IL244506A patent/IL244506B/en active IP Right Grant
2017
- 2017-04-05 ZA ZA2017/02410A patent/ZA201702410B/en unknown

Also Published As

Publication number	Publication date
BR112016005271A2 (pt)	2020-05-12
MX2016002881A (es)	2016-04-21
US9458118B2 (en)	2016-10-04
MY181928A (en)	2021-01-14
WO2015038533A2 (en)	2015-03-19
EP3043787A4 (en)	2017-02-01
ZA201702410B (en)	2019-06-26
AU2014318979A1 (en)	2016-03-03
PH12016500296A1 (en)	2016-05-16
AU2014318979B2 (en)	2019-03-28
CA2922851C (en)	2023-03-14
IL244506B (en)	2020-02-27
US20160221974A1 (en)	2016-08-04
CN105611923B (zh)	2019-08-23
SG10201805552PA (en)	2018-08-30
CA2922851A1 (en)	2015-03-19
SG11201601367QA (en)	2016-03-30
ES2687598T3 (es)	2018-10-26
EP3043787A2 (en)	2016-07-20
UA120353C2 (uk)	2019-11-25
CN105611923A (zh)	2016-05-25
WO2015038533A3 (en)	2015-10-29
IL244506A0 (en)	2016-04-21
JP2016532716A (ja)	2016-10-20
RU2016113156A3 (2)	2018-07-02
RU2016113156A (ru)	2017-10-16
EP3043787B1 (en)	2018-09-05
US20160130239A1 (en)	2016-05-12
JP6445565B2 (ja)	2018-12-26

Legal Events

Date	Code	Title	Description
2016-04-08	PA0105	International application	Patent event date: 20160408 Patent event code: PA01051R01D Comment text: International Patent Application
2016-05-16	PG1501	Laying open of application
2019-09-09	A201	Request for examination
2019-09-09	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20190909 Comment text: Request for Examination of Application
2021-06-04	E902	Notification of reason for refusal
2021-06-04	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20210604 Patent event code: PE09021S01D
2021-11-18	E601	Decision to refuse application
2021-11-18	PE0601	Decision on rejection of patent	Patent event date: 20211118 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210604 Comment text: Notification of reason for refusal Patent event code: PE06011S01I

Publication	Publication Date	Title
EP3043787B1 (en)	2018-09-05	Sodium channel modulators for the treatment of pain and diabetes
US10179781B2 (en)	2019-01-15	Sodium channel modulators for the treatment of pain
TW201040186A (en)	2010-11-16	Phthalazine-containing antidiabetic compounds
TW200946524A (en)	2009-11-16	Certain chemical entities, compositions and methods
JP6754828B2 (ja)	2020-09-16	ピリジン及びピリミジン誘導体
US20170304306A1 (en)	2017-10-26	SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES
CA3088968C (en)	2023-10-17	Dihydroindolizinone derivative
JP7527039B2 (ja)	2024-08-02	Ｇｌｕｔ１欠損症症候群の治療に使用するためのイソキノリン誘導体
TW202330472A (zh)	2023-08-01	化合物、組合物及使用方法
HK1224572A1 (en)	2017-08-25	Sodium channel modulators for the treatment of pain and diabetes
WO2008067713A1 (fr)	2008-06-12	Composés à structure de cyclopentane, leurs procédés de préparation et leurs utilisations médicales
US20220280644A1 (en)	2022-09-08	"TRPswitch" - A STEP FUNCTION CHEMO-OPTOGENETIC LIGAND